SOX14 Antibody
-
中文名稱：SOX14兔多克隆抗體
-
貨號：CSB-PA022422ESR1HU
-
規(guī)格：￥440
-
圖片：
-
Immunohistochemistry of paraffin-embedded human glioma using CSB-PA022422ESR1HU at dilution of 1:100
-
-
其他：
產(chǎn)品詳情
-
產(chǎn)品名稱：Rabbit anti-Homo sapiens (Human) SOX14 Polyclonal antibody
-
Uniprot No.：
-
基因名：SOX14
-
別名：SOX14 antibody; SOX28 antibody; Transcription factor SOX-14 antibody; Protein SOX-28 antibody
-
宿主：Rabbit
-
反應種屬：Human
-
免疫原：Recombinant Human Transcription factor SOX-14 protein (91-240AA)
-
免疫原種屬：Homo sapiens (Human)
-
標記方式：Non-conjugated
-
克隆類型：Polyclonal
-
抗體亞型：IgG
-
純化方式：Antigen Affinity Purified
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
-
產(chǎn)品提供形式：Liquid
-
應用范圍：ELISA, IHC
-
推薦稀釋比：
Application Recommended Dilution IHC 1:20-1:200 -
Protocols：
-
儲存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評價
相關產(chǎn)品
靶點詳情
-
功能：Acts as a negative regulator of transcription.
-
基因功能參考文獻：
- High SOX14 expression is associated with bladder cancer. PMID: 28258492
- these results demonstrate that SOX14 can promote proliferation and invasion capacity of cervical cancer cells by activating the Wnt/beta-catenin pathway. PMID: 25973056
- identified the positive control element and provided the first evidence that FOXA2 is involved in up-regulation of SOX14 expression in HepG2 and U87MG cell lines PMID: 20074681
-
亞細胞定位：Nucleus.
-
數(shù)據(jù)庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC
Species Reactivity: Human
-
-
-
-
-
